Home > Healthcare > Pharmaceuticals > Vaccines > Live Attenuated Vaccines Market

Live Attenuated Vaccines Market Share

Report ID: GMI8782
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

Live Attenuated Vaccines Market Share

In the live attenuated vaccines industry, numerous key players are engaged in competition to secure market share. They drive innovation through significant R&D investments, striving to introduce novel vaccine formulations and expand their product portfolios. Moreover, supported by robust distribution networks, strategic partnerships, and regulatory approvals, these companies maintain a strong competitive position worldwide, facilitating sustained growth and market leadership.

Live Attenuated Vaccines Market Companies

Prominent players operating in the live attenuated vaccines market are as mentioned below:

Abbott
Bharat Biotech International Limited
Boehringer Ingelheim International GmbH
GlaxoSmithKline, plc.
Haffkine Biopharmaceutical Corporation Limited
HBI
Merck & Co.
Novartis Pharmaceuticals Corporation
Sanofi
Serum Institute of India Ltd.
Valneva SE
Zydus Group

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global live attenuated vaccines market crossed USD 14.5 billion in 2023 and is expected to reach USD 35.6 billion by 2032, due to the increasing incidences of viral and bacterial infections worldwide.

The viral vaccines type segment held a significant share in 2023 and is set to grow at 10.3% CAGR between 2024 – 2032, driven by a higher prevalence of viral diseases globally.

North America live attenuated vaccines industry held a decent market share in 2023 and is anticipated to reach USD 12 billion by 2032, owing to the presence of advanced research facilities.

Boehringer Ingelheim International GmbH, GlaxoSmithKline, plc., Haffkine Biopharmaceutical Corporation Limited, HBI, Merck & Co., Sanofi, Serum Institute of India Ltd., Valneva SE, Zydus Group among others